Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

Masataka Takenaka; Martin Köbel; Dale W. Garsed; Sián Fereday; Ahwan Pandey; Dariush Etemadmoghadam; Joy Hendley; Ayako Kawabata; Daito Noguchi; Nozomu Yanaihara; Hiroyuki Takahashi; Takako Kiyokawa; Masahiro Ikegami; Hirokuni Takano; Seiji Isonishi; Kazuhiko Ochiai; Nadia Traficante; Sreeja Gadipally; Timothy Semple; Dane Vassiliadis; Kaushalya Amarasinghe; Jason Li; Gisela Mir Arnau; Aikou Okamoto; Michael Friedländer; David D.L. Bowtell

doi:10.1158/1078-0432.ccr-18-3691

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Survival benefit following chemotherapy in OCCC was not associated with pathological misclassification of tumor histotype. HNF1B loss may help identify the subset of patients with OCCC with a more favorable outcome.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Takenaka et al. (2019) studied this question.

synapsesocial.com/papers/69d94d7600ab073a27835ed3 https://doi.org/10.1158/1078-0432.ccr-18-3691

View at Publisher

Ask AI

Bookmark

Share

Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

Ask about this paper

Abstract

Discussion

Cite This Study

Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading